Saturday 17 October 2026 Export MEDP’s income statement to Excel — free account

Medpace Holdings, Inc.

Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS grew 36.4% and free cash flow fell 3.03%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for ten.

618.47 10.13 −1.61%

Follow MEDP

Alert me

Market cap: $17.6B
P/E: 35.6×
Fwd P/E: 26.7×
Dividend yield: —
F-score: 8/9
Altman Z: 8.04
Beneish M: −2.92
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 439.35

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	11	2	—	—	1	—	1	—	2	12	6	—

Insider Ownership 19.54%

Capital & Financial Ratios $m

Market Cap 17,550.00

Revenue 2,782.29

Net Income 491.50

Free Cash Flow 706.69

Net Debt (502.69)

Current Ratio 0.73

Debt/Equity 0.00

P/E ratio 35.56

Fwd P/E 26.70

P/S ratio 6.26

P/B ratio 40.16

Past 5Y EPS Growth 31.81%

This Y EPS Growth 15.24%

Next Y EPS Growth 9.91%

Next Y revenue growth 12.72%

Next 5Y EPS Growth 12.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 62.02%

10-year low 10-year high

P/S against its own 10 years 87.17%

10-year low 10-year high

P/B against its own 10 years 94.49%

10-year low 10-year high

EV/Sales against its own 10 years 88.44%

10-year low 10-year high

EV/FCF against its own 10 years 82.81%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	245	669	497	503
Receivables	298	296	402	442
Inventory	—	—	—	—
Other	—	—	—	—
	594	1,029	990	1,050

	2023	2024	2025	Q'26
Payables	32	33	28	38
ST’ Debt	—	—	—	—
Other	600	764	907	947
	925	1,105	1,344	1,435

Compound Annual Growth %

	10y	5y	3y
Sales	21.56%	22.27%	20.12%
Cash Flow	23.58%	22.49%	22.49%
Earnings	0.00%	25.50%	22.51%
Book Value	1.05%	(10.64%)	5.91%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	707	707	—	—	—
’25	559	603	660	708	2,530
’24	511	528	533	537	2,109
’23	434	461	492	498	1,886
’22	331	351	384	394	1,460
’21	260	278	296	309	1,142
’20	231	205	230	260	926

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	152	162	—	—	—
’25	126	149	246	193	713
’24	153	116	149	191	609
’23	80	83	114	156	433
’22	46	97	108	137	388
’21	57	63	72	71	263
’20	49	44	60	105	259

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	145	138	—	—	—
’25	116	142	235	188	682
’24	147	104	139	183	572
’23	71	74	106	146	397
’22	37	85	101	127	351
’21	51	57	66	62	235
’20	44	35	51	98	227

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	4.28	4.25	—	—	—
’25	3.67	3.10	3.86	4.67	15.28
’24	3.20	2.75	3.01	3.67	12.63
’23	2.27	1.93	2.22	2.46	8.88
’22	1.69	1.46	2.05	2.12	7.28
’21	1.14	1.06	1.29	1.32	4.81
’20	0.76	0.64	1.09	1.35	3.84

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	26.51	21.76	31.75	48.18	58.72	130.74	126.95	167.00	277.72	250.05	Analyst estimates 2026–2028 Powerpack
	High	38.94	39.64	65.09	86.71	150.57	231.00	235.72	317.57	459.77	626.26
People
People	Employees	2,500	2,500	2,900	3,500	3,600	4,500	5,200	5,900	5,900	6,200
	Revenue/emp, $m	0.17	0.17	0.24	0.25	0.26	0.25	0.28	0.32	0.36	0.41
Income, $m
Income, $m	Revenue	422	436	705	861	926	1,142	1,460	1,886	2,109	2,530
	Gross margin, %	52.91	51.45	64.19	62.72	61.72	61.39	63.36	66.16	67.66	71.06
	EBT	22	57	94	125	169	202	283	336	476	542
	EBT margin, %	5.21	13.06	13.33	14.50	18.20	17.67	19.37	17.80	22.57	21.44
	Net income	13	39	73	100	145	182	245	283	404	451
	Depreciation	61	38	32	23	19	21	22	26	29	28
Per share, $
Per share, $	Revenue	11.81	11.17	19.82	24.00	25.98	31.85	45.08	61.38	68.13	87.72
	Earnings	0.38	1.00	2.05	2.79	4.07	5.06	7.57	9.20	13.06	15.64
	Cash flow	2.57	2.49	4.41	5.63	7.26	7.34	11.98	14.11	19.67	24.73
	Capex	(0.38)	(0.31)	(0.45)	(0.50)	(0.88)	(0.79)	(1.14)	(1.19)	(1.18)	(1.09)
	Free cash flow	2.19	2.18	3.95	5.13	6.38	6.55	10.84	12.91	18.49	23.64
	Book value	17.11	12.89	16.59	20.24	22.61	26.57	11.93	18.19	26.67	15.91
	Shares, m	36	39	36	36	36	36	32	31	31	29
Valuation, ×
Valuation, ×	P/E	90.29	37.14	25.20	30.13	34.20	43.01	27.37	33.22	25.44	35.87
	P/S	3.04	3.33	2.67	3.50	5.36	6.83	4.62	4.98	4.88	6.40
	P/B	2.10	2.88	3.19	4.15	6.16	8.19	17.46	16.80	12.46	35.29
	EV/Sales	3.41	3.83	2.81	3.43	5.13	6.49	4.67	4.91	4.61	6.25
	EV/FCF	18.37	19.52	14.08	16.04	20.91	31.55	19.43	23.33	17.00	23.19
Cash, $m
Cash, $m	Operating cash flow	92	97	157	202	259	263	388	433	609	713
	Capex	(14)	(12)	(16)	(18)	(31)	(28)	(37)	(37)	(37)	(31)
	Free cash flow	78	85	141	184	227	235	351	397	572	682
Balance, $m
Balance, $m	Working capital	(35)	(63)	(79)	(26)	34	134	(470)	(331)	(75)	(354)
	Total debt	192	248	106	11	16	16	50	—	—	—
	Net debt	155	222	83	(121)	(262)	(445)	22	(245)	(669)	(497)
	Shareholders’ equity	611	504	590	726	806	953	386	559	826	459
Returns, %
Returns, %	ROA	1.37	4.05	7.60	9.49	11.44	11.92	16.29	18.80	21.52	22.13
	ROIC	4.29	5.59	9.39	13.14	19.19	24.45	42.68	67.15	178.91	0.00
	ROE	2.62	7.02	13.34	15.22	18.92	20.68	36.64	59.83	58.42	70.23

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DGX Quest Diagnostics Incorporated	$26.4B	24.6×	20.8×	+10.21% (above 0%: growing)	+14.74% (above 0%: growing)	+5.28% (above 0%: growing)	33.75%	15.08%	Compare
LH Labcorp Holdings Inc.	$26.4B	26.2×	19.0×	+5.78% (above 0%: growing)	+28.42% (above 0%: growing)	−42.01% (below 0%: shrinking)	29.80%	12.10%	Compare
GH Guardant Health, Inc.	$22.3B	— (loss-making)	— (loss-making)	+44.33% (above 0%: growing)	n/m	−5.46% (below 0%: shrinking)	65.39%	(38.55%)	Compare
MEDP Medpace Holdings, Inc.	$17.6B	35.6×	26.7×	+17.24% (above 0%: growing)	+36.39% (above 0%: growing)	−3.03% (below 0%: shrinking)	71.36%	20.76%
RVTY Revvity Inc.	$17.3B	72.7×	37.5×	+1.31% (above 0%: growing)	+2.17% (above 0%: growing)	+59.29% (above 0%: growing)	57.13%	12.24%	Compare
CRL Charles River Laboratories International, Inc.	$14.6B	— (loss-making)	29.6×	−2.72% (below 0%: shrinking)	n/m	−12.22% (below 0%: shrinking)	36.19%	11.94%	Compare
ICLR ICON PLC	$13.5B	254×	23.8×	+1.20% (above 0%: growing)	−59.31% (below 0%: shrinking)	+109.66% (above 0%: growing)	23.23%	6.68%	Compare
QGEN QIAGEN N.V.	$9.5B	23.6×	17.5×	+0.28% (above 0%: growing)	+7.94% (above 0%: growing)	+30.45% (above 0%: growing)	63.62%	24.75%	Compare
TWST Twist Bioscience Corporation	$9.5B	— (loss-making)	— (loss-making)	+23.24% (above 0%: growing)	n/m	−7.23% (below 0%: shrinking)	52.76%	(30.65%)	Compare
Median of peers	$15.9B	26.2×	22.3×	+3.54%	+7.94%	−0.09%	44.48%	12.02%

All 52 Diagnostics & Research stocks →

Medpace Holdings, Inc. (MEDP) key facts

Strength: Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
Medpace Holdings, Inc. (MEDP) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MEDP traded at $618.47, a market capitalization of $17.6 billion.
Return on equity was 70.2% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 8.04 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.